GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Long-Term Capital Lease Obligation

Paion Ag (Paion Ag) Long-Term Capital Lease Obligation : $0.44 Mil (As of Jun. 2023)


View and export this data going back to 2005. Start your Free Trial

What is Paion Ag Long-Term Capital Lease Obligation?

Paion Ag's Long-Term Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.44 Mil.

Paion Ag's quarterly Long-Term Capital Lease Obligation declined from Jun. 2022 ($0.54 Mil) to Dec. 2022 ($0.48 Mil) and declined from Dec. 2022 ($0.48 Mil) to Jun. 2023 ($0.44 Mil).

Paion Ag's annual Long-Term Capital Lease Obligation increased from Dec. 2020 ($0.02 Mil) to Dec. 2021 ($0.64 Mil) but then declined from Dec. 2021 ($0.64 Mil) to Dec. 2022 ($0.48 Mil).

Paion Ag Long-Term Capital Lease Obligation Historical Data

The historical data trend for Paion Ag's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paion Ag Long-Term Capital Lease Obligation Chart

Paion Ag Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.02 0.64 0.48

Paion Ag Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.75 0.64 0.54 0.48 0.44

Paion Ag  (OTCPK:PAIOF) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Paion Ag Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Paion Ag's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Paion Ag (Paion Ag) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Paion Ag (OTCPK:PAIOF) » Definitions » Long-Term Capital Lease Obligation
Comparable Companies
FRA:SPB HAM:GWK3 STU:DWB FRA:BBI HAM:TLG ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX HKSE:03692 TSE:4507 NSE:DIVISLAB BOM:500124 BOM:532321
Traded in Other Exchanges
PA8:Germany
Address
Heussstrasse 25, Aachen, DEU, 52078
Website
https://www.paion.com
Paion Ag is a holding company engaged in providing various services to the subsidiaries. The group is focused on developing and commercializing medical innovations for procedural sedation, anesthesia, and critical care services. The key product of the company is remimazolam, which is an ultra-short-acting intravenous benzodiazepine sedative. In the human body, remimazolam is rapidly metabolized to an inactive metabolite by tissue esterases and not metabolized by cytochrome-dependent hepatic pathways. The organization is based in Germany.